HPV vaccines: Global perspectives
HPV vaccines: Global perspectives
复制标题
DOI：
10.1080/21645515.2017.1289301
复制
发表时间：
2017-01-01
影响因子：
4.8
通讯作者：
Patel, Pankaj R.
中科院分区：
文献类型：
--
作者：
Gupta, Gaurav;Glueck, Reinhard;Patel, Pankaj R.
HPV 作为 HPV 相关恶性肿瘤和疾病的病因学因素的发现为预防和治疗开辟了多种机会。目前市售的 HPV 疫苗（Gardasil、Gardasil 9 和 Cervarix）本质上是预防性的，源自含有佐剂的 L1 型 HPV 病毒样颗粒。在全球范围内，通过多项临床试验，发现它们非常安全和有效。某些限制，例如成本效益、针对所有 HPV 类型的覆盖率较低以及 3 剂接种计划等，使得这些疫苗难以在全球范围内使用。解决这些问题的方法包括使用 L1 或替代抗原 (L2) 的替代表达系统，以及优化剂量和扩大保护范围，以提供廉价且具有交叉保护性的疫苗。此外，我们自己使用毕赤酵母等替代宿主和基于抗原递送系统的麻疹载体进行的研究显示出有希望的临床前免疫原性，有潜力开发为下一代 HPV 预防性疫苗。其他几种治疗方法也在进行中。
The discovery of HPV as the etiological factor for HPV-associated malignancies and disease has opened up several opportunities for prevention and therapy. Current commercially available HPV vaccines (Gardasil, Gardasil 9, and Cervarix) are prophylactic in nature and derived from adjuvanted L1-based virus-like particles of HPV. Globally, through several clinical trials, they were found to be very safe and efficacious. Certain limitations such as cost-effectiveness, low coverage against all HPV types and a 3-dose schedule make these vaccines difficult to use worldwide. Approaches to address these issues involve alternate expression systems using L1 or alternate antigen (L2) as well as optimizing doses and broadening protection to provide cheap and cross-protective vaccines. Additionally, promising preclinical immunogenicity results from our own studies using alternative hosts such as Pichia and an antigen delivery system-based measles vector have potential for development as next generation HPV prophylactic vaccines. Several other therapeutic approaches are also ongoing.